Institutional members access full text with Ovid®

Share this article on:

FDA Lifts Restrictions on Rosiglitazone

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: April 2014 - Volume 114 - Issue 4 - p 24
doi: 10.1097/01.NAJ.0000445681.44930.17
Drug Watch
  • The Food and Drug Administration has lifted many of the restrictions it had placed on the type 2 antidiabetic drug rosiglitazone (Avandia) in 2011.
  • Reevaluation of data from a major clinical trial indicated that rosiglitazone did not increase the risk of cardiovascular events as had been previously suggested.

Diane S. Aschenbrenner recently retired as course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch :

© 2014 Lippincott Williams & Wilkins. All rights reserved.